Sanofi (ADR)

NYSE: SNY
$47.89
-$0.49 (-1.0%)
Closing price September 20, 2021
Wednesday's top analyst upgrades, downgrades and initiations included AECOM, Albermarle, Apple, Chesapeake Energy, Foot Locker, Gap, GoPro, Nike, Qualcomm, Southwest Airlines, Under Armour and...
After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and U.S. Food and Drug Administration (FDA) updates in February and March.
The included top analyst upgrades, downgrades and initiations seen on Tuesday Apptio, AT&T, Bain Capital, Comerica, First Solar, Palo Alto Networks, Pfizer, Travelers and Ulta Beauty.
The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero Energy and Zynga.
2018 has been a strange time for investors. While the U.S. stock market sits close to all-time highs, many of the emerging and other developed markets nations have seen their shares take a beating....
The more recent observations about Buffett's portfolio changes coming into mid-2018 have been quite different than many of the historic and traditional Buffett picks.
The include top analyst upgrades, downgrades and other research calls from Wednesday Akamai Technologies, Apple, AutoZone, Dropbox, Electronic Arts, Ford, Kinder Morgan, Pandora Media, Procter &...
Regeneron Pharmaceuticals and Sanofi are committing to lowering the price of the anti-cholesterol drug Praluent.
The top analyst upgrades, downgrades and other research calls from Friday include Albermarle, Allergan, Boston Scientific, eBay, FedEx, Gogo, LendingTree, Nokia, UPS and Vertex Pharmaceuticals.
24/7 Wall St. has tracked many of the so-called whale watching trades made by America's top investment managers, hedge fund managers and independent investors.
Bioverativ is adding to Monday’s M&A news after it was announced that Sanofi would be acquiring the firm.
Alnylam Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage trial in patients with hereditary ATTR amyloidosis with polyneuropathy.
Here are 10 of the most notable top picks from Credit Suisse in European equities for U.S. investors.
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.